Pipeline of Atrial Fibrillation Therapeutics for H2 2015 Studied in New Research Report

23 Nov, 2015, 07:30 ET from ReportsnReports

PUNE, India, November 23, 2015 /PRNewswire/ --

New market research "Atrial Fibrillation - Pipeline Review, H2 2015" covers global therapeutic landscape of Atrial Fibrillation and reviews key pipeline products under drug profile section which include product description, MoA and R&D brief, licensing and collaboration details & other developmental activities.

Complete report on Atrial Fibrillation Pipeline Review spread across 107 pages with 35 tables and 15 figures is now available at http://www.reportsnreports.com/reports/440484-atrial-fibrillation-pipeline-review-h2-2015.html .

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this report include ARCA biopharma, Inc., Armetheon, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Cardiome Pharma Corp., Daiichi Sankyo Company, Limited, Gilead Sciences, Inc., Isis Pharmaceuticals, Inc., Laboratoires Pierre Fabre SA, Nissan Chemical Industries, Ltd., Nyken BV, Otsuka Holdings Co., Ltd. and Xention Limited. Drug Profiles mentioned in this report are AT-300, BMS-394136, BMS-919373, bucindolol hydrochloride, budiodarone, edoxaban tosylate, F-373280, ISIS-CRPRx, NIP-151, NYK-1112, OMT-33, OPC-108459, ranolazine ER, Small Molecule to Block Calcium-Activated Potassium Channel for Atrial Fibrillation, Small Molecule to Block Kv1.5 for Atrial Fibrillation, Small Molecule to Block Kv1.5, Nav1.5, IKACh for Atrial Fibrillation, Small Molecules to Block Voltage Gated Sodium Channel for Atrial Fibrillation, vanoxerine, vernakalant hydrochloride, XEN-R0702, XEND-0103, XENR-0703 and XENR-0706.

Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=440484 .

Scope of this report: The report reviews key players involved in the therapeutics development for Atrial Fibrillation and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Atrial Fibrillation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, a detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Atrial Fibrillation pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Another newly published market research titled Myocardial Infarction - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Myocardial Infarction Pipeline Review research report of 333 pages is available at http://www.reportsnreports.com/reports/435358-myocardial-infarction-pipeline-review-h2-2015.html .

Explore more reports on Pharmaceuticals market available with ReportsnReports.com.

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com


SOURCE ReportsnReports